J. Goldman & CO LP Avidity Biosciences, Inc. Transaction History
J. Goldman & CO LP
- $3.53 Billion
- Q4 2024
A detailed history of J. Goldman & CO LP transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 13,600 shares of RNA stock, worth $423,232. This represents 0.01% of its overall portfolio holdings.
Number of Shares
13,600Holding current value
$423,232% of portfolio
0.01%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RNA
# of Institutions
257Shares Held
108MCall Options Held
517KPut Options Held
717K-
Price T Rowe Associates Inc Baltimore, MD11MShares$344 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$294 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$268 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.11MShares$252 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY7.93MShares$247 Million3.76% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.62B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...